Company Description
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome.
It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes.
It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018.
Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Dec 4, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 147 |
| CEO | Omid Farokhzad |
Contact Details
Address: 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 United States | |
| Phone | 650 453 0000 |
| Website | seer.bio |
Stock Details
| Ticker Symbol | SEER |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001726445 |
| CUSIP Number | 81578P106 |
| ISIN Number | US81578P1066 |
| Employer ID | 82-1153150 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Omid C. Farokhzad M.D., Ph.D. | Founder, Chief Executive Officer, and Chair of the Board of Directors |
| David R. Horn | President,Treasurer and Chief Financial Officer |
| Joe Laws | Chief Technology Officer and Co-Founder |
| Kenny Ross | Chief Operations and Product Officer |
| Marissa Dixon | Chief People Officer |
| Dr. Serafim Batzoglou Ph.D. | Chief Data Officer |
| Martin Goldberg Ph.D. | Senior Vice President of Development |
| Dr. Asim Siddiqui Ph.D. | Senior Vice President of Research and Tech Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 7, 2024 | 8-K | Current Report |
| Aug 16, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Aug 2, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jul 19, 2024 | 8-K | Current Report |
| Jul 12, 2024 | 8-K | Current Report |
| Jul 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |